pfizer glp 1 drug Is on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ADA '26: Lilly's dominance, Pfizer's

Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats

2 In addition to lifestyle modifications (diet and exercise), many pharmacologic strategies have been proposed to counter iatrogenic weight gain, including appetite suppressants (eg, pro-dopaminergic agents such as phentermine, stimulants, and amantadine), pro-anorectant anticonvulsants (eg, topiramate or zonisamide), opioid receptor antagonists (eg, olanzapine/samidorphan or naltrexone) and oral hypoglycemics such as metformin

Gastrointestinal intolerance, particularly nausea and vomiting, may affect adherence despite their tendency to diminish over time (Liu et al., 2022)

10.1186/s12933-022-01604-7

10.1038/nrgastro.2015.204 [DOI] [PubMed] [Google Scholar] Weina H., Yuhu N., Christian H., Birong L., Feiyu S., Le W

These effects do not significantly differ between various GLP-1R agonists